In the Press

Filters
Type
Sectors
Geography
Companies

Sign up for our free
equity research notes

Register
1640 Results
Embed
Investment trust insider on Partners Group Private Equity

James Carthew: It may be in wind-down but this trust is still too cheap Shareholders in Partners Group Private Equity (PEY) earlier this month voted overwhelmingly to approve its managed wind down. It plans to make semi-annual returns of cash to investors from March next year but will continue to buy back shares (targeting €15m […]

Investment Trust Insider on Perpetual Income and Growth
Matthew Read comments on possible clean exit for USF in Investment Week

Matthew Read comments on USF’s wind-down and possible buyer in Robin Amos’ article: “With USF in wind-down, a clean exit with greater certainty over the proceeds, rather than an earn-out arrangement, also has to be preferable at this stage. That said, regulatory approval could take up to five months and while the progress on due […]

Biotech trusts top performance charts in February
Investment trust insider on Marwyn Value Investors

James Carthew: The complex investment company that may become my top performer In net asset value (NAV) terms, Marwyn Value Investors (MVI) is the best-performing UK smaller companies trust over three years and ranks pretty highly over five years, too, with a NAV return of 84% over that period, but it trades on a 46% […]

Investment Trust Insider on Perpetual Income and Growth
Richard Williams comments on Scottish Oriental review in Portfolio Adviser

Richard Williams comments on the SST tender being cancelled in Patrick Sanders’ article: “Consolidation now looks a distinct possibility.” Read the article here

Richard Williams comments on the proxy advisers’ verdict on USA and Saba

Richard Williams comments on the proxy advisers’ recommendation to vote against Saba in Michael Nelson’s article: “However, proxy adviser recommendations are not binding, and Saba’s voting power means much will depend on the participation of other shareholders, making turnout crucial if the board is to fend off the challenge,” Read the article here

Biotech trusts top performance charts in February
Matthew Read comments on SSIT’s new investment in Investment Week

Matthew Read comments on SSIT’s further investment in Skylo in Robin Amos’ article: “Ultimately, Skylo will still need to translate its technological promise into sustained commercial success, but the investment also illustrates how the C share fundraising has given SSIT the firepower to stand its corner during fundraisings for promising holdings rather than risk dilution […]

Biotech trusts top performance charts in February
Matthew Read comments on Saba’s NBPE stake in Portfolio Adviser

Matthew Read comments on NBPE’s strategy in the face of Saba in Patrick Sanders’ article: “Given that NBPE has been generating meaningful realisations and recycling capital into new opportunities, we think there remains a credible case for allowing the existing strategy to run its course,” Read the article here  

Matthew Read’s SSIT research quoted in ii

Matthew Read’s research note on SSIT and his comments on the C shares feature in Dave Baxter’s article: Read the article here  

David Batchelor comments on SSIT’s new finance for Xona in Sharesify

David Batchelor comments on SSIT’s Xona cash deployment in James Crux’s article: “This latest development also illustrates the advantages of SSIT’s position within the wider Seraphim investment ecosystem, which allows it to back promising businesses through successive funding rounds.” Read the article here

Matthew Read comments on JUSC/BASC merger in Investment Week

Matthew Read comments on the US smallers funds merger in Michael Nelson’s article: “This may not be the outcome BASC’s board envisaged when the review began, but it looks like a pragmatic solution that gives shareholders a genuine choice while avoiding the risk of leaving behind a subscale trust.” Read the article here

Biotech trusts top performance charts in February